Navigation Links
Identafi(TM) 3000 Picked by Dentistry Today Magazine as One of the Top 100 Products of 2009
Date:7/1/2009

HOUSTON, July 1 /PRNewswire/ -- Trimira LLC's Identafi(TM) 3000 oral cancer detection device has been picked by leading dental industry magazine Dentistry Today as one of its Top 100 Products. The full results of the 23rd annual competition will be published in the July issue.

Dentistry Today noted that The Top 100 Products are selected based on reader response and represent what's new and innovative in the dental profession. Identafi(TM) 3000 is the most powerful and accurate device for screening dental patients to reveal signs of oral cancer and pre-cancer. The device incorporates next-generation oral cancer-detection "multispectral" technology that is changing the screening and diagnostic landscape for dentists and doctors across the nation.

Identafi(TM) 3000's multispectral (triple-wavelength) optical technology was developed by a team of research scientists at America's top-rated and largest cancer center, the University of Texas M.D. Anderson Cancer Center in Houston, in collaboration with Houston's Rice University and British Columbia Cancer Research Centre in Vancouver, Canada.

Identafi 3000 represents a quantum leap in the visualization of mucosal abnormalities, including oral cancer or premalignant dysplasia. The technology not only is effective in screening and diagnosing oral cancers but also has application in diagnosing cervical, gastrointestinal, skin, and bladder cancers. Unlike other methods, Identafi 3000 empowers doctors and dentists to pinpoint biochemical and morphological changes in cells.

Identafi(TM) 3000 is made by Houston-based Trimira LLC, which is venture capital-funded by cancer research philanthropist T. Boone Pickens of oil and windfarming fame.

About TRIMIRA(TM) LLC

TRIMIRA(TM) LLC is a subsidiary of Remicalm LLC, a privately held medical device and optical imaging company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

Visit TRIMIRA(TM) at: http://www.trimira.net/


'/>"/>
SOURCE TRIMIRA(TM) LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Identafi(TM) 3000 Identifies Signs of Silent Killer:
2. Hospital Chain and Hand Picked Union, SEIU, Forced to Cancel Rigged Election After Protests by RNs and Other Employees
3. RNs Denounce Sham Election in Nine Ohio Hospitals, Hospital Chain Seeks to Impose Hand-Picked Union
4. American Dental Association, The Forsyth Institute Collaborate to Pilot Evidence-Based Dentistry Training Course
5. American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines
6. New ... Provisional Restorations In Dentistry DVD by Paul R. Chalifoux, DDS
7. National Museum of Dentistry Opens New Smile Experience, Exhibition Recognizes Dr. Irwin Smigel as Father of Aesthetic Dentistry
8. Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry
9. Dentistry and Mass Disasters: A Dentists Role as a First Responder During a Public Health Emergency
10. Davis Vision, Visionworks, United Concordia Dental and Louisiana State University School of Dentistry Partner with Hands on New Orleans
11. Milestone Scientific to Exhibit at the CDA Art and Science of Dentistry Spring Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... On 2 March 2017, the United ... Operations Command’s Patriot Award. The award was presented by the USSOCOM Commander, General ... for its significant and enduring support to the command. , Accepting the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change the ...
(Date:3/23/2017)... Las Vegas, Nevada (PRWEB) , ... March 23, 2017 , ... ... March 25th from 10am - 2pm. All events will be located in the ... will be hosting a no-cost Child ID event. No appointment is necessary and each ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, testimony ... Europe for public health and the environment and is calling on the United States ... the overwhelming support of European citizens, the European Union (EU) will, beginning next year, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Insight 2022" drug pipelines to their offering. ... Global Immune ... gives comprehensive insight on clinical and non-clinical aspects involved in ... main streamline drugs in the immunotherapy treatment. Report helps to ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 7.1% over the next decade to reach approximately $129.81 ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
Breaking Medicine Technology: